Compare GEL & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEL | TSHA |
|---|---|---|
| Founded | 1996 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1996 | 2020 |
| Metric | GEL | TSHA |
|---|---|---|
| Price | $15.03 | $5.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $19.50 | $11.63 |
| AVG Volume (30 Days) | 176.7K | ★ 4.0M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,912,770,000.00 | $9,773,000.00 |
| Revenue This Year | $12.12 | N/A |
| Revenue Next Year | N/A | $1,152.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.60 | 17.28 |
| 52 Week Low | $13.75 | $2.54 |
| 52 Week High | $18.64 | $7.30 |
| Indicator | GEL | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 57.87 | 41.19 |
| Support Level | $14.89 | $5.28 |
| Resistance Level | $16.31 | $5.51 |
| Average True Range (ATR) | 0.42 | 0.45 |
| MACD | 0.12 | -0.08 |
| Stochastic Oscillator | 79.31 | 11.46 |
Genesis Energy LP focuses on the midstream segment of the crude oil and natural gas industry. It offers various services to crude oil and natural gas producers, and industrial and commercial enterprises. The company's reportable segments are: Offshore pipeline transportation, Marine transportation, and Onshore transportation and services. Maximum revenue is generated from the Offshore pipeline transportation segment, which includes the transportation and processing of crude oil and natural gas in the Gulf of America. The Marine transportation segment provides waterborne transportation of petroleum products and crude oil throughout North America; and the Onshore transportation and services segment deals with crude oil logistics, sour gas processing, and sells sulfur byproducts.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.